early detection of diabetic neuropathy
management of diabetic foot
new device
Innovative diagnostic device
new early-diagnostic method
prototype device
foot care
late diagnosis of diabetic foot results
early stage
diabetes patients
innovation project
new competitive advantages
physicians
market potential
European market
nurses
dominant costs
Phase
substantial health-care costs
clinical validation
efficient dependable method
better clinical outcomes
increased number of amputations
patient’s suffering
commercialisation
objective
users
accelerated growth
strategic business plan
economic viability
strong case
common complication
EU-wide challenge
personalised medicine
condition
commercial output
policy
capacity
total healthcare expenditures
main need
VibroSense’s
identified niche
Current methods
appropriate treatment
loss of sensation
disruptiveness
needs